Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy.
Diabetic nephropathy is characterized by an accumulation of mesangium matrix that correlates well with the loss of kidney function. High glucose concentration is known to increase the synthesis of many matrix components. Recently, we have shown that degradation of matrix also decreases in diabetes. The major enzymes responsible for matrix degradation are the matrix metalloproteinases. The physiology of these enzymes is complex and their activity is tightly regulated at many levels. At the transcriptional level matrix metalloproteinase (MMP) expression is increased by protein kinase C (PKC) agonists, and some growth factors. In contrast transforming growth factor (TGF)-beta can decrease MMP expression. Once synthesized, MMPs are secreted as inactive pro-enzymes that are activated by other MMPs or plasmin. To effect this, plasmin must be liberated from plasminogen in the pericellular environment. In turn, activated MMPs can be inhibited by binding to specific inhibitors known as tissue inhibitor of metalloproteinases (TIMP). Cell culture and animal studies have shown that high glucose (HG) decreases expression of MMPs and increases expression of TIMPs. HG can also affect MMP activation by decreasing plasmin availability and reducing expression of a membrane-bound MMP called MT1-MMP. How HG induces these changes remains to be fully elucidated. One possibility is that HG can increase TGF-beta. which may in turn alter MMP promoter activity: this area is currently being studied in our laboratory.
McLennan
S V
SV
Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. sue@earth.endocrin.usyd.edu.au
Fisher
E
E
Martell
S Y
SY
Death
A K
AK
Williams
P F
PF
Lyons
J G
JG
Yue
D K
DK
D000818:Animals; D003928:Diabetic Nephropathies / Q000209:etiology*; D004789:Enzyme Activation; D005341:Fibrinolysin / Q000502:physiology*; D005920:Glomerular Mesangium / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000502:physiology*; D010958:Plasminogen / Q000502:physiology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000502:physiology; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000502:physiology
D019715:Tissue Inhibitor of Metalloproteinase-1; D016212:Transforming Growth Factor beta; D010958:Plasminogen; D005341:Fibrinolysin; D020782:Matrix Metalloproteinases; D005947:Glucose